Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Meta-analysis of Efficacy of Topotecan
- Conditions
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2010-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01160185
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 110
- Registration Number
- NCT01121406
- Locations
- 🇧🇪
1230.18.32003 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪1230.18.32004 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1230.18.32002 Boehringer Ingelheim Investigational Site, Gent, Belgium
A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)
- Conditions
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01076400
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT01039025
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Regulatory Hycamtin(Oral) PMS
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 92
- Registration Number
- NCT01037023
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Duke University
- Target Recruit Count
- 80
- Registration Number
- NCT01004874
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 6
- Registration Number
- NCT01003938
- Locations
- 🇺🇸
Bellevue Hospital Center, New York, New York, United States
🇺🇸NYU Clinical Cancer Center, New York, New York, United States
🇺🇸Tisch Hospital, New York, New York, United States
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 361
- Registration Number
- NCT00976911
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇩🇪Klinikum Nord Frauenklinik, Nürnberg, Germany
🇧🇪UZ Antwerpen, Edegem, Belgium
Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
- Conditions
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2009-04-28
- Lead Sponsor
- Centre Francois Baclesse
- Target Recruit Count
- 39
- Registration Number
- NCT00888810
- Locations
- 🇫🇷
Centre François Baclesse, Caen, Calvados, France
🇫🇷Centre G-F Leclerc, Dijon, France
🇫🇷Institut Bergonié, Bordeaux, France
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT00808899
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.